Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized placebo-controlled study of BIIB122 in LRRK2-associated Parkinson's disease
MOH_2025-10-26_015406Phase 2Not yet recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BIIB122 in Parkinson's disease (PD) (3 arms), sponsored by Denali Therapeutics Inc. Primary endpoint: Safety and tolerability of BIIB122. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
BIIB122
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on MOH_2025-10-26_015406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-10-26_015406.